Host factors impacting the innate response in humans to the candidate adjuvants RC529 and monophosphoryl lipid A

Vaccine

Volumn 22, Issue 11-12, 2004, Pages 1515-1523

  Tiberio, Lorrie ^a   Fletcher, Leah ^a   Eldridge, John H ^a   Duncan, David D ^a,b  

^a WYETH RESEARCH   (United States)

^b NONE   (United States)

Author keywords

Adjuvant; Genotype; TLR4

Indexed keywords

BACTERIUM LIPOPOLYSACCHARIDE; CYTOKINE; HOST FACTOR 1; IMMUNOLOGICAL ADJUVANT; INTERLEUKIN 10; INTERLEUKIN 6; INTERLEUKIN 8; PHOSPHORYL LIPID A; RC 529; TOLL LIKE RECEPTOR 4; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ADULT; ALLELE; ARTICLE; BLOOD ANALYSIS; CONTROLLED STUDY; FEMALE; GENOTYPE; HUMAN; HUMAN EXPERIMENT; IMMUNE RESPONSE; IMMUNE RESPONSE GENE; IMMUNOMODULATION; IMMUNOPHARMACOLOGY; IMMUNOSTIMULATION; IN VITRO STUDY; MALE; NORMAL HUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN POLYMORPHISM; RECEPTOR UPREGULATION; STATISTICAL SIGNIFICANCE;

ADJUVANTS, IMMUNOLOGIC; ADOLESCENT; ADULT; ALLELES; CYTOKINES; DNA; DNA PRIMERS; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; FLOW CYTOMETRY; GENOTYPE; HUMANS; KINETICS; LIPID A; LIPOPOLYSACCHARIDES; MALE; MEMBRANE GLYCOPROTEINS; MIDDLE AGED; PHENOTYPE; POLYMORPHISM, GENETIC; RECEPTORS, CELL SURFACE; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; SEX CHARACTERISTICS; SIGNAL TRANSDUCTION; TOLL-LIKE RECEPTOR 4; TOLL-LIKE RECEPTORS;

EID: 1842508975     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2003.10.019     Document Type: Article

References (62)

1. Aderem A., Ulevitch R.J. Toll-like receptors in the induction of the innate immune response. Nature. 406:2000;782-787.
2. Ozinsky A., Underhill D.M., Fontenot J.D., Hajjar A.M., Smith K.D., Wilson C.B. The repertoire for pattern recognition of pathogens by the innate immune system is defined by cooperation between Toll-like receptors. Proc. Natl. Acad. Sci. U.S.A. 97:2000;13766-13771.
3. Underhill D.M., Ozinsky A. Phagocytosis of microbes: complexity in action. Annu. Rev. Immunol. 20:2002;825-852.
4. Reis e Sousa C. Dendritic cells as sensors of infection. Immunity. 14:2001;495-498.
5. Sethi S., Lipford G., Wagner H., Kretzschmar H. Postexposure prophylaxis against prion disease with a stimulator of innate immunity. Lancet. 360:2002;229-230.
6. Gustafson G.L., Rhodes M.J. A rationale for the prophylactic use of monophosphoryl lipid A in sepsis and septic shock. Bioch. Biophys. Res. Commun. 182:1992;269-275.
7. Haziot A., Hijiya N., Gangloff S.C., Silver J., Goyert S.M. Induction of a novel mechanism of accelerated bacterial clearance by lipolysaccharide in CD14-deficient and Toll-like receptor 4-deficient mice. J. Immunol. 166:2001;1075-1078.
8. Karima R., Matsumoto S., Higashi H., Matsushima K. The molecular pathogenesis of endotoxic shock and organ failure. Mol. Med. Today. 5:1999;123-132.
9. Kaisho T., Akira S. Toll-like receptors as adjuvant receptors. Biochim. Biophys. Acta. 1589:2002;1-13.
10. Schnare M., Barton G.M., Holt A.C., Takeda K., Akira S., Medzhitov R. Toll-like receptors control activation of adaptive immune responses. Nat. Immunol. 2:2001;947-950.
11. Zuany-Amorim C., Hastewell J., Walker C. Toll-like receptors as potential therapeutic targets for multiple diseases. Nat. Rev. Drug Disc. 1:2002;797-807.
12. Greenberg L., Fleming D.S. Increased efficiency of diphtheria toxoid when combined with pertussis vaccine. Can. J. Public Health. 38:1947;279-282.
13. Alving C.R. Lipopolysaccharide, lipid A, and liposomes containing lipid A as immunologic adjuvants. Immunobiolgy. 187:1993;430-446.
14. Ulrich JT, Myers KR. Monophosphoryl lipid A as an adjuvant. In: Powell MF, Newman MJ, Burdman JR, editors. Vaccine design. The subunit and adjuvant approach. 1st ed. Plenum Press: New York; 1995. p. 495-524.
15. Johnson D.A., Keegan D.S., Sowell C.G., Livesay M.T., Johnson C.L., Taubner L.M.et al. 3-O-desacyl monophosphoryl lipid A derivatives: synthesis and immunostimulant activities. J. Med. Chem. 42:1999;4640-4649.
16. Johnson D.A., Sowell C.G., Johnson C.L., Livesay M.T., Keegan D.S., Rhodes M.J.et al. Synthesis and biological evaluation of a new class of vaccine adjuvants: aminoalkyl glucosaminide 4-phosphates (AGPs). Bioorg. Med. Chem. Lett. 9:1999;2273-2278.
17. Baldridge J.R., Cluff C.W., Evans J.T., Lacy M.J., Stephens J.R., Brookshire V.G.et al. Immunostimulatory activity of aminoalkyl glucosaminide 4-phosphates (AGPs): induction of innate immune responses by RC-524 and RC-529. J. Endotoxin Res. 8:2002;453-458.
18. Kiechl S., Lorenz E., Reindl M., Wiedermann C.J., Oberhollenzer F., Bonora E.et al. Toll-like receptor 4 polymorphisms and atherogenesis. N. Engl. J. Med. 347:2002;185-192.
19. Lorenz E., Mira J.P., Frees K.L., Schwartz D.A. Relevance of mutations in the TLR4 receptor in patients with gram-negative septic shock. Arch. Intern. Med. 162:2002;1028-1032.
20. Arbour N.C., Lorenz E., Schutte B.C., Zabner J., Kline J.N., Jones M.et al. TLR4 mutations are associated with endotoxin hyporesponsiveness in humans. Nat. Genet. 25:2000;187-191.
21. Haukim N., Bidwell J.L., Smith A.J.P., Keen L.J., Gallagher G., Kimberly R.et al. Cytokine gene polymorphism in human disease: on-line databases. Genes Immun. 3(Suppl 2):2002;313-330.
22. Fishman D., Faulds G., Jeffery R., Mohamed-Ali V., Yudkin J.S., Humphries S.et al. The effect of novel polymorphisms in the interleukin-6 (IL-6) gene on IL-6 transcription and plasma IL-6 levels, and an association with systemic-onset juvenile chronic arthritis. J. Clin. Invest. 102:1998;1369-1376.
23. Hull J., Thomson A., Kwiatkowski D. Association of respiratory syncytial virus bronchiolitis with the interleukin 8 gene region in UK families. Thorax. 55:2000;1023-1027.
24. Turner D.M., Williams D.M., Sankaran D., Lazarus M., Sinnott P.J., Hutchinson I.V. An investigation of polymorphism in the interleukin-10 gene promoter. Eur. J. Immunogen. 24:1997;1-8.
25. Crawley E., Kay R., Sillibourne J., Patel P., Hutchinson I., Woo P. Polymorphic haplotypes of the interleukin-10 5′ flanking region determine variable interleukin-10 transcription and are associated with particular phenotypes of juvenile rheumatoid arthritis. Arthritis Rheum. 42:1999;1101-1108.
26. Gibson A.W., Edberg J.C., Wu J., Westendorp R.G.J., Huizinga T.W.J., Kimberly R.P. Novel single nucleotide polymorphisms in the distal IL-10 promoter affect IL-10 production and enhance the risk of systemic lupus erythematosus. J. Immunol. 166:2001;3915-3922.
27. Westendorp R.G.J., van Dunne F.M., Kirkwood T.B.L., Helmerhorst F.M., Huizinga T.W.J. Optimizing human fertility and survival. Nat. Med. 7:2001;873.
28. Hajeer A.H., Hutchinson I.V. Influence of TNFα gene polymorphisms on TNFα production and disease. Hum. Immunol. 62:2001;1191-1199.
29. Pociot F., Wilson A.G., Nerup J., Duff G.W. No independent association between a tumor necrosis factor-alpha promotor region polymorphism and insulin-dependent diabetes mellitus. Eur. J. Immunol. 23:1993;3050-3053.
30. Montgomery DC. Design and analysis of experiments. 5th ed. New York: Wiley; 2001.
31. Poltorak A., He X., Smirnova I., Liu M.Y., Van Huffel C., Du X.et al. Defective LPS signaling in C3H/HeJ and C57BL/10ScCr mice: mutations in Tlr4 gene. Science. 282:1998;2085-2088.
32. Qureshi S.T., Larivière L., Leveque G., Clermont S., Moore K.J., Gros P.et al. Endotoxin-tolerant mice have mutations in Toll-like receptor 4 (Tlr4). J. Exp. Med. 189:1999;615-625.
33. Hoshino K., Takeuchi O., Kawai T., Sanjo H., Ogawa T., Takeda Y.et al. Toll-like receptor 4 (TLR4)-deficient mice are hyporesponsive to lipopolysaccharide: evidence for TLR4 as the Lps gene product. J. Immunol. 162:1999;3749-3752.
34. Perera P.Y., Mayadas T.N., Takeuchi O., Akira S., Zaks-Zilberman M., Goyert S.M.et al. CD11b/CD18 acts in concert with CD14 and Toll-like receptor (TLR) 4 to elicit full lipopolysaccharide and taxol-inducible gene expression. J. Immunol. 166:2001;574-581.
35. Johnson A.G., Tomai M.A., Chen Y., Odean M. A comparison of the immunomodulating properties of two forms of monophosphoryl lipid A analogues. J. Immunother. 10:1991;398-404.
36. Hiernaux J.R., Stashak P.W., Cantrell J.L., Rudbach J.A., Baker P.J. Immunomodulatory activity of monophosphoryl lipid A in C3H/HeJ and C3H/HeSnJ mice. Infect. Immun. 57:1989;1483-1490.
37. Salkowski C.A., Detore G.R., Vogel S.N. Lipopolysaccharide and monophosphoryl lipid A differentially regulate interleukin-12, gamma interferon, and interleukin-10 mRNA production in murine macrophages. Infect. Immun. 65:1997;3239-3247.
38. Rudbach J.A., Keegan D.S., Sowell C.G. Calculating therapeutic indices and therapeutic advantages for endotoxins and monophosphoryl lipid A: an evaluation of data from the scientific literature. J. Endotoxin Res. 2:1995;301-310.
39. Hornung V., Rothenfusser S., Britsch S., Krug A., Jahrsdörfer B., Giese T.et al. Quantitative expression of Toll-like receptor 1-10 mRNA in cellular subsets of human peripheral blood mononuclear cells and sensitivity to CpG oligodexoynucleotides. J. Immunol. 168:2002;4531-4537.
40. Asai K., Hiki N., Mimura Y., Ogawa T., Unou K., Kaminishi M. Gender differences in cytokine secretion by human peripheral blood mononuclear cells: role of estrogen in modulating LPS-induced cytokine secretion in an ex vivo septic model. Shock. 16:2001;340-343.
41. Heesen M., Bloemeke B., Heussen N., Kunz D. Can the interleukin-6 response to endotoxin be predicted? Studies of the influence of a promoter polymorphism of the interleukin-6 gene, gender, the density of the endotoxin receptor CD14, and inflammatory cytokines. Crit. Care Med. 30:2002;664-669.
42. Reuss E., Fimmers R., Kruger A., Becker C., Rittner C., Höhler T. Differential regulation of interleukin-10 production by genetic and environmental factors - a twin study. Genes Immun. 3:2002;407-413.
43. Majetschak M., Christensen B., Obertacke U., Waydhas C., Schindler A.E., Nast-Kolb D.et al. Sex differences in post-traumatic cytokine release of endotoxin-stimulated whole blood: relationship to the development of severe sepsis. J. Trauma Inj. Infect. Crit. Care. 48:2000;832-839.
44. Wichmann M.W., Inthorn D., Andress H.J., Schildberg F.W. Incidence and mortality of severe sepsis in surgical intensive care patients: the influence of patient gender on disease process and outcome. Intensive Care Med. 26:2000;167-172.
45. Schröder J., Kahlke V., Staubach K.H., Zabel P., Stüber F. Gender differences in human sepsis. Arch. Surg. 133:1998;1200-1205.
46. Lorenz E., Schwartz D.A., Martin P.J., Gooley T., Lin M.T., Chien J.W.et al. Association of TLR4 mutations and the risk for acute GVHD after HLA-matched-sibling hematopoietic stem cell transplantation. Biol. Blood Marrow Transplant. 7:2001;384-387.
47. Read R.C., Pullin J., Gregory S., Borrow R., Kaczmarski E.B., di Giovine F.S.et al. A functional polymorphism of Toll-like receptor 4 is not associated with likelihood or severity of meningococcal disease. J. Infect. Dis. 184:2001;640-642.
48. Smirnova I., Mann N., Dols A., Derkx H.H., Hibberd M.L., Levin M.et al. Assay of locus-specific genetic load implicates rare Toll-like receptor 4 mutations in meningococcal susceptibility. Proc. Natl. Acad. Sci. U.S.A. 100:2003;6075-6080.
49. Westendorp R.G.J., Langermans J.A.M., Huizinga T.W.J., Elouali A.H., Verweij C.L., Boomsma D.I.et al. Genetic influence on cytokine production and fatal meningococcal disease. Lancet. 349:1997;170-173.
50. de Jong B.A., Westendorp R.G.J., Bakker A.M., Huizinga T.W.J. Polymorphisms in or near tumour necrosis factor (TNF)-gene do not determine levels of endotoxin-induced TNF production. Genes Immun. 3:2002;25-29.
51. Yan H., Yuan W., Velculescu V.E., Vogelstein B., Kinzler K.W. Allelic variation in human gene variation. Science. 297:2002;1143.
52. Jordanides N., Eskdale J., Stuart R., Gallagher G. Allele associations reveal four prominent haplotypes at the human interleukin-6 (IL-6) locus. Genes Immun. 1:2000;451-455.
53. Terry C.F., Loukaci V., Green F.R. Cooperative influence of genetic polymorphisms on interleukin 6 transcriptional regulation. J. Biol. Chem. 275:2000;18138-18144.
54. Hull J., Ackerman H., Isles K., Usen S., Pinder M., Thomson A.et al. Unusual haplotypic structure of IL8, a susceptibility locus for a common respiratory virus. Am. J. Hum. Genet. 69:2001;413-419.
55. Eskdale J., Gallagher G., Verweij C.L., Keijsers V., Westendorp R.G.J., Huizinga T.W.J. Interleukin 10 secretion in relation to human IL-10 locus haplotypes. Proc. Natl. Acad. Sci. U.S.A. 95:1998;9465-9470.
56. Eskdale J., Keijsers V., Huizinga T., Gallagher G. Microsatellite alleles and single nucleotide polymorphisms (SNP) combine to form four major haplotype families at the human interleukin-10 (IL-10) locus. Genes Immun. 1:1999;151-155.
57. Waldron-Lynch F., Adams C., Amos C., Zhu D.K., McDermott M.F., Shanahan F.et al. Tumor necrosis factor 5′ promoter single nucleotide polymorphisms influence susceptibility to rheumatoid arthritis (RA) in immunogenetically defined multiplex RA families. Genes Immun. 2:2001;82-87.
58. Drysdale C.M., McGraw D.W., Stack C.B., Stephens J.C., Judson R.S., Nandabalan K.et al. Complex promoter and coding region b2-adrenergic receptor haplotypes alter receptor expression and predict in vivo responsiveness. Proc. Natl. Acad. Sci. U.S.A. 97:2000;10483-10488.
59. Baldini M., Lohman I.C., Halonen M., Erickson R.P., Holt P.G., Martinez F.D. A polymorphism in the 5′ flanking region of the CD14 gene is associated with circulating soluble CD14 levels and with total serum immunoglobulin E. Am. J. Respir. Cell Mol. Biol. 20:1999;976-983.
60. Miterski B., Böhringer S., Klein W., Sindem E., Haupts M., Schimrigk S.et al. Inhibitors in the NFkB cascade comprise prime candidate genes predisposing to multiple sclerosis, especially in selected combinations. Genes Immun. 3:2002;211-219.
61. De Becker G., Moulin V., Pajak B., Bruck C., Francotte M., Thiriart C.et al. The adjuvant monophosphoryl lipid A increases the function of antigen-presenting cells. Int. Immunol. 12:2000;807-815.
62. Ismaili J., Rennesson J., Aksoy E., Vekemans J., Vincart B., Amraoui Z. et al. Monophosphoryl lipid A activates both human dendritic cells and T cells. J. Immunol. 168:2002;926-932.